AlphaCentric Advisors’s Travere Therapeutics TVTX Stock Holding History

AlphaCentric Advisors’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-19,640	Closed	-$442K	–	278
2023 Q1	$442K	Buy	19,640 +1,000	+5%	+$21.3K	0.3%	93
2022 Q4	$392K	Buy	+18,640	New	+$395K	0.39%	84
2021 Q3	–	Sell	-61,500	Closed	-$897K	–	218
2021 Q2	$897K	Buy	+61,500	New	+$1.21M	0.24%	29

Other funds holding TVTX

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

AlphaCentric Advisors's TVTX Position: Q2 2023 in Review

AlphaCentric Advisors sold out of Travere Therapeutics (TVTX) in Q2 2023, closing a stake of 19,640 shares — an estimated $442K sold.

AlphaCentric Advisors first reported a position in TVTX in Q2 2021 and held it in 3 quarters. The position peaked at $897K in Q2 2021. 169 funds tracked by Wall St. Rank hold TVTX as of Q2 2023.

AlphaCentric Advisors reported no remaining Travere Therapeutics position as of Q2 2023 after selling out during the quarter.
AlphaCentric Advisors sold 19,640 Travere Therapeutics shares in Q2 2023, an estimated $442K.
AlphaCentric Advisors first reported a position in Travere Therapeutics in Q2 2021 and held it in 3 quarters.
AlphaCentric Advisors's Travere Therapeutics position peaked at $897K in Q2 2021.
169 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2023.

Based on AlphaCentric Advisors's 13F filing for Q2 2023, filed 8 Aug 2023.